CIRIUM
29.12.2020 08:02:09 CET | Business Wire | Press release
Global aviation data firm Cirium today released its new Airline Insights Review 2020 which reveals the shocking impact on aviation of worldwide travel restrictions to curb COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201228005254/en/
The report shows that the pandemic and its consequences wiped out 21 years of global passenger traffic growth in a matter of months, reducing traffic this year to levels last seen in 1999. In comparison to last year, passenger traffic is estimated to be down 67% in 2020.
At the peak of the disruption in April, scheduled passenger flights dropped significantly to just 13,600 globally on April 25, compared to the year’s busiest day on January 3 when Cirium tracked over 95,000 scheduled passenger flights globally. This marks an extraordinary 86% reduction in flights.
From January to December airlines operated 49% fewer flights in 2020 compared to 2019 – down from 33.2 million flights to just 16.8 million (to December 20).
Domestic travel was down 40% this year, from 21.5 million flights in 2019, while international flights suffered an even more precipitous drop as they were 68% below the 11.7 million flights tracked the year before.
Jeremy Bowen, CEO of Cirium, said: “This severe setback shows the true extent of the challenge faced by the struggling aviation sector as it has sought to reset itself in the new post COVID-19 era.”
“Whereas this time last year we were celebrating the on-time performance of global carriers, this year is dramatically different. Most global airlines were largely on time in 2020; it’s just a shame that the traveling public, airlines and aviation firms worldwide didn’t benefit.
“The factors which usually cause delay, such as congested airspace, taxiways and late connecting passengers simply did not exist in 2020.”
The Cirium Airline Insights Review 2020 replaces Cirium’s annual On-Time Performance Review which for more than a decade has identified the world’s best performing airlines and airports for on-time flight operations.
NEW AIRLINE INSIGHTS REVIEW: FLIGHTS FLOWN DRAMATICALLY DOWN
Global passenger traffic figures reveal a plunge of over two thirds (67%) versus the previous year, with Asia-Pacific continuing to handle over a third of world passenger traffic.
The majority of the scheduled passenger flights flown this year have been domestic – totaling 13 million (77%) with a mere 3.8 million (23%) flying internationally, due to closed borders and limited business travel.
Cirium data analysis recorded Southwest Airlines operating the most flights globally (and in North America), with 854,800 flights in total. Meanwhile, China Southern Airlines (487,700 flights) topped the tables in the Asia-Pacific, Ryanair in Europe (205,000 flights), Azul in Latin America (134,000 flights) and Qatar Airways (82,400 flights) in the Middle East and Africa.
On the ground, Atlanta was the world’s busiest airport, handling over 245,000 arriving flights during 2020, while the world’s busiest air route in both directions was within South Korea, between Seoul and the island of Jeju with 70,700 flights operated.
Forward planning for airlines has dramatically contracted from six- to 12-months for flight scheduling to just six- to eight-weeks – forcing carriers to be nimbler and adapt with greater speed to the rapidly changing rules and travel restrictions around the world.
FLEETS IN STORAGE (BUT NOT THE A320)
As airlines have been forced to drastically reduce the number of aircraft still in service, those still flying are operating significantly fewer hours.
For example, narrowbody aircraft operated just six to seven hours a day in Q3 2020 compared to nine to 10 hours a day in the same period last year.
While up to 30% of the global passenger fleet remains in storage there are signs of recovery on the horizon, with only 10% of short-haul Airbus A320neo aircraft currently in storage showing narrowbody aircraft leading the recovery and domestic and short-haul travel returning first.
With domestic and short-haul services ruling the day, the world’s most used aircraft type was the Airbus A320 with Cirium tracking 5.49 million flights throughout 2020.
SEVEN TRENDS IDENTIFIED BY CIRIUM
“Airlines will have a way before returning to 2019 levels particularly as international travel is significantly down and showing only slow signs of recovery, mainly China and Southeast Asia,” Jeremy Bowen added.
“But Cirium is confident aviation will weather this difficult and terrible year and emerge in better shape – with younger more fuel-efficient aircraft and right-sized fleets – to gradually navigate their way to recovery in the years ahead.”
The seven key trends outlined by The Cirium Airline Insights Review 2020 for next year include:
- The consolidation of airlines , particularly in Asia-Pacific where more domestic competitors will merge or be acquired.
- New-generation aircraft like the A320neo and the return of the 737 Max, will provide reduced operating costs.
- Surplus aircraft will be retired and the Boeing 747 and the Airbus A380 are projected to support the rising demand in the denser leisure markets.
- In Q4 we saw a 78% plunge in bookings compared to the same period last year – this will naturally change the way the industry forecasts demand , we are seeing on-line search and sentiment becoming the primary indicators to calculate demand.
- Airlines will need to deploy more dynamic scheduling with the increased volatility of flight scheduling, as the booking window has fallen from six- to 12-months to just six- to eight-weeks.
- The implementation of AI technology will accelerate to automate the traveler experience and real-time proactive information will become more critical.
- Aircraft leasing will push past 50% becoming the major manner in which aircraft are financed .
To read the full Cirium Airline Insights Review 2020 – click here.
Bowen thanked the OTP board members comprised of Henry Harteveldt at Atmosphere Research group and Dr. Mario Hardy at Pacific Asia Travel Association (PATA) for their insights and contributions to the Airline Insight Review 2020.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
